Fig. (1).

Paralytic disease severity and course in placebo- and E2-treated bone marrow chimeric mice with EAE. (A) Esr2−/− → WT, n = 6 placebo, n = 6 E2; (B) WT → Esr2−/−, n = 9 placebo, n = 9 E2; (C) WT → Esr1−/−, n = 10 placebo, n = 10 E2. Chimeras were evaluated for engraftment 6 – 8 weeks after bone marrow transplant and selected for further study. E2 or placebo pellets (60 days time-release) were implanted one week prior to disease induction, 8 – 10 weeks after bone marrow transplant. Mice were followed daily for 20 days after immunization with MOG peptide.

* p < 0.01; ** p < 0.001.